Tesamorelin Peptide: FDA-Approved GHRH Analog Research Profile (Egrifta)

What Is Tesamorelin?

Tesamorelin (TH9507) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence stabilized by trans-3-hexenoic acid conjugation at the N-terminus. This chemical modification dramatically extends the compound's biological half-life compared to native GHRH while preserving full receptor binding activity and downstream pituitary growth hormone (GH) secretory capacity.

Tesamorelin is the only FDA-approved GHRH analog (approved in 2010 as Egrifta, updated to Egrifta SV in 2019) for treatment of excess abdominal fat in HIV-infected patients with lipodystrophy — a metabolic side effect of antiretroviral therapy. This clinical approval makes tesamorelin unique among GHRH analogs in having extensive phase II and phase III human clinical data demonstrating both efficacy and safety, which significantly enhances its research value compared to non-approved analogs.

The compound stimulates GH secretion through an entirely physiological mechanism — acting directly on pituitary somatotroph cells via GHRH receptors — rather than bypassing normal GH axis regulation. This physiological quality preserves the pulsatile GH release pattern and maintains downstream IGF-1 feedback mechanisms, distinguishing it from supraphysiological approaches to GH axis stimulation.

References

• •PMID: 42538058
• •PMID: 42395176
• •PMID: 42382101

> Research Use Only: All information in this article is for educational and research purposes. Tesamorelin is available as a prescription medication (Egrifta SV) for a specific approved indication only. Nothing herein constitutes medical advice. Researchers should consult applicable regulatory guidelines before handling this compound.

Mechanism of Action

GHRH Receptor Binding and Activation

Tesamorelin binds with high affinity to the GHRH receptor (GHRH-R), a class B G protein-coupled receptor expressed predominantly on pituitary somatotroph cells. The receptor binding triggers:

1. Gαs coupling: Stimulatory G protein activation

2. Adenylate cyclase activation: Increased cAMP production from ATP

3. PKA activation: cAMP-dependent protein kinase activation

4. CREB phosphorylation: Transcription factor activation for GH gene expression

5. Calcium influx: Voltage-gated calcium channel opening → secretory granule fusion

6. GH release: Exocytosis of pre-formed GH from secretory granules

The trans-3-hexenoic acid N-terminal modification in tesamorelin confers resistance to dipeptidyl peptidase IV (DPP-IV) cleavage — the primary enzymatic mechanism for endogenous GHRH degradation. This single modification extends plasma half-life approximately 4–8 fold compared to native GHRH while the compound retains full pharmacological activity.

Pulsatile GH Release Preservation

A defining pharmacological characteristic of tesamorelin research is the preservation of physiological GH secretory pulsatility. Unlike synthetic GH administration which delivers a continuous, non-pulsatile hormone load, tesamorelin acts upstream at the pituitary level, allowing normal hypothalamic-pituitary feedback to shape the resulting GH profile.

Studies monitoring GH secretion during tesamorelin administration demonstrate:

• •GH pulses maintain their physiological timing and amplitude modulation
• •Peak GH concentrations remain within clinically relevant ranges (3–15 ng/mL depending on baseline somatotroph function)
• •Normal somatostatin counterregulation remains intact, preventing runaway GH elevation
• •Overnight GH pulse amplitude and frequency are preserved under tesamorelin dosing conditions

This pulsatile preservation is mechanistically important: pulsatile GH appears to elicit different transcriptional responses in liver and adipose tissue compared to continuous GH exposure, potentially affecting how downstream metabolic effects manifest.

Downstream GH/IGF-1 Axis Effects

GH released following tesamorelin administration acts on multiple tissues:

Liver (primary IGF-1 production):

• •GH stimulates hepatic IGF-1 synthesis and secretion
• •IGF-1 serves as the primary anabolic mediator of GH's tissue effects
• •Hepatic IGF-1 production governs the negative feedback inhibiting further GH release from the pituitary (via somatostatin)

Adipose tissue (direct GH effects):

• •GH is directly lipolytic in adipose tissue, activating hormone-sensitive lipase
• •Visceral adipose tissue (VAT) is particularly sensitive to GH's lipolytic effects
• •Subcutaneous fat responds less robustly to GH's direct lipolytic actions
• •This depot-specific selectivity underlies tesamorelin's visceral fat reduction efficacy

Muscle tissue:

• •GH promotes nitrogen retention and protein synthesis (partially IGF-1 mediated)
• •GH increases uptake of amino acids into muscle
• •Muscle mass preservation is supported through anti-catabolic mechanisms

Bone:

• •GH and IGF-1 together promote bone mineral density through osteoblast stimulation
• •Bone remodeling effects are relevant throughout adult life in subjects with GH deficiency

Visceral Fat Reduction Mechanism

The clinical indication of tesamorelin — visceral adiposity reduction — involves multiple convergent mechanisms:

1. Direct lipolysis: GH activates hormone-sensitive lipase in visceral adipocytes

2. Insulin sensitization: Reduced visceral fat improves insulin signaling

3. Adipokine normalization: Decreased visceral fat reduces pro-inflammatory adipokines (TNF-α, IL-6)

4. FFA liberation and oxidation: GH-stimulated free fatty acid release increases hepatic and muscular beta-oxidation

5. IGF-1 effects: IGF-1 promotes peripheral glucose uptake, improving metabolic efficiency

Visceral adipose tissue contains significantly higher density of GH receptors compared to subcutaneous fat, explaining the depot-selective reduction observed in tesamorelin clinical trials.

Clinical Research Overview: FDA Approval and HIV Lipodystrophy Trials

Background: HIV Lipodystrophy Syndrome

HIV lipodystrophy syndrome (HIVLS) develops in patients on antiretroviral therapy (ART) — particularly older nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors. The syndrome includes:

• •Visceral fat accumulation in the abdomen (lipohypertrophy)
• •Loss of peripheral subcutaneous fat (lipoatrophy)
• •Dyslipidemia (elevated triglycerides, reduced HDL)
• •Insulin resistance

The excess visceral adiposity carries cardiovascular risk independent of the HIV infection itself, making effective treatment a meaningful clinical objective. GHRH analogs emerged as candidates because HIV patients with lipodystrophy show relative GH deficiency, with reduced GH pulse amplitude contributing to metabolic dysregulation.

Phase II Dose-Finding Research

Early phase II studies established tesamorelin's dose-efficacy relationship and safety profile in HIV-positive individuals with excess abdominal fat. Key findings:

• •Dose range of 1–2 mg/day subcutaneous injection demonstrated significant VAT reduction
• •2 mg/day emerged as the optimal dose balancing efficacy and tolerability
• •IGF-1 elevations were dose-dependent and remained within physiological ranges
• •Injection site reactions were the most common adverse event

Phase III Randomized Controlled Trials

Tesamorelin's FDA approval rested on two pivotal phase III randomized, double-blind, placebo-controlled trials:

• •N = 412 HIV-positive individuals with excess abdominal fat
• •Tesamorelin 2 mg/day vs placebo for 26 weeks
• •Primary endpoint: Visceral adipose tissue area change by CT scan
• •Result: Tesamorelin reduced VAT by −15.2% vs. +5.0% increase in placebo group
• •Secondary: Waist circumference reduced, triglycerides improved, patient-reported body image improved

Study 2 (long-term extension):

• •Subjects re-randomized at week 26: responders continued or switched to placebo
• •Confirmed that benefits reversed within approximately 6–12 months of discontinuation
• •52-week data showed sustained VAT reduction with continued tesamorelin therapy
• •Safety profile remained acceptable over the full 52-week period

Pooled Analysis Results:

• •VAT reduction: approximately 15–18 cm² by CT measurement
• •Responder rate (~≥8% VAT reduction at 26 weeks): approximately 70–75%
• •Trunk fat reduction by DEXA: statistically significant
• •Total body fat: not significantly changed (visceral-selective effect)
• •Lean mass: maintained or slightly increased

Egrifta SV (Updated Formulation, 2019)

In 2019, the FDA approved Egrifta SV, a new 2 mg/mL tesamorelin formulation designed to improve ease of use. Key updates:

• •Single vial, ready-to-mix formulation simplifying preparation
• •Same clinical indication as original Egrifta
• •Bioequivalence to the original formulation confirmed
• •Reduced reconstitution steps compared to original lyophilized form

Body Composition Research: Visceral Adipose Tissue Reduction

CT-Measured VAT Changes

CT scanning is the gold-standard measure of visceral adipose tissue used in tesamorelin trials. Measurements are typically performed at the L4-L5 vertebral level and expressed as cross-sectional area in cm².

Key data from published tesamorelin research:

Triglycerides and Cardiometabolic Risk

Tesamorelin's metabolic effects extend beyond visceral fat reduction:

• •Triglycerides decrease by 50–100 mg/dL in many subjects (particularly in those with elevated baseline TG)
• •This effect is partly mediated by reduced hepatic triglyceride production from decreased visceral fat flux
• •LDL cholesterol: generally unchanged
• •HDL cholesterol: modestly improved in some trials
• •Cardiovascular risk composite scores (Framingham, D:A:D) improved in multiple analyses

The triglyceride effect is potentially significant for HIV patients already at elevated cardiovascular risk from ART regimens and immune dysregulation.

Insulin Resistance Considerations

An important counterbalancing effect of GH on carbohydrate metabolism is increased insulin resistance:

• •GH directly antagonizes insulin signaling in peripheral tissues
• •IGF-1 (which rises with tesamorelin) has opposing insulin-sensitizing effects
• •Net glucose metabolism effects in tesamorelin trials: glucose modestly elevated in some studies, HbA1c largely unchanged
• •Subjects with diabetes or pre-diabetes require monitoring during tesamorelin research
• •The VAT reduction benefits on insulin sensitivity largely offset but do not fully counteract direct GH-mediated insulin resistance

Cognitive Function Research: Emerging Evidence

Theoretical Framework

The potential cognitive benefits of tesamorelin have attracted research interest through several mechanistic pathways:

1. GH/IGF-1 on brain: Both GH and IGF-1 receptors are expressed in brain regions critical for cognition (hippocampus, prefrontal cortex)

2. Neuroprotective IGF-1 effects: IGF-1 promotes neuronal survival, synaptic plasticity, and neurogenesis in preclinical models

3. Metabolic improvement → cognitive benefit: Reducing visceral fat and improving insulin sensitivity may independently benefit cerebral metabolism

4. HIV-associated neurocognitive disorder (HAND): HIV-positive subjects already have elevated rates of mild cognitive impairment, creating a population where cognitive effects could be detectable

Clinical Cognitive Research in HIV Population

The most relevant published human research comes from studies in HIV-infected individuals. Specifically:

Bhaskaran et al. and related studies examined cognitive function in tesamorelin-treated HIV subjects using standardized neuropsychological batteries:

• •Domains assessed: attention, processing speed, executive function, verbal memory
• •Some studies showed improvement in specific domains (particularly processing speed and executive function) in tesamorelin versus placebo groups
• •Effect sizes were modest but statistically significant in some analyses
• •Correlations were observed between IGF-1 increases and cognitive improvement, suggesting IGF-1 as a potential mediator

Limitations of current cognitive research:

• •Trials were not primarily designed or powered for cognitive endpoints
• •HIV-specific neurotoxic factors complicate interpretation
• •Sample sizes for cognitive subanalyses were limited
• •Longer-duration cognitive studies in non-HIV populations are lacking

Relevance to Non-HIV Populations

Research is ongoing regarding whether tesamorelin's cognitive effects generalize beyond the HIV population. Theoretical applicability includes:

• •Age-related GH decline (somatopause) as a contributor to cognitive aging
• •Metabolic syndrome + cognitive impairment shared pathophysiology
• •Potential in mild cognitive impairment studies (preliminary, no established data)

This area remains preliminary and represents an active direction in GHRH analog research rather than an established benefit.

Tesamorelin vs. Sermorelin vs. CJC-1295: Research Comparison

For researchers selecting a GHRH analog, the key comparators are sermorelin, CJC-1295, and tesamorelin. See also the full GHRH Analogs Compared guide.

Structural Comparison

Clinical Evidence Depth

Tesamorelin has the strongest human evidence base of any GHRH analog with:

• •Two pivotal Phase III randomized controlled trials
• •FDA approval with an established NDA
• •Published pharmacokinetic data in humans
• •Approved patient labeling with full safety database

Sermorelin has historical clinical data from the 1990s supporting GH secretagogue activity but lacked the Phase III program needed for modern metabolic indications. Its research value lies in shorter duration, well-studied GHRH receptor agonism.

CJC-1295 DAC has essentially no published controlled clinical trials. Its extremely long half-life creates a non-pulsatile GH profile (more similar to GH replacement), which carries different mechanistic implications and uncertain long-term safety profile compared to pulsatile-preserving GHRH analogs.

Research Protocol Considerations

Research Protocols from Published Studies

Dosing Parameters from Clinical Literature

All tesamorelin dosing data presented here derives from published FDA-reviewed clinical trials. This is for research reference only.

Standard research dose (from Phase III trials):

• •Dose: 2 mg tesamorelin per day
• •Route: Subcutaneous injection
• •Injection site: Abdomen (rotating sites)
• •Timing: Once daily, consistent timing (evening administration in most trials)
• •Duration: Studies conducted at 26 weeks, 52 weeks, and 104 weeks

Phase II dose range studied: 0.5–4 mg/day; 2 mg/day selected as optimal

Non-responder definition in trials: <8% VAT reduction at 26 weeks (approximately 25–30% of subjects)

Biomarker Monitoring in Research Protocols

Published tesamorelin studies used the following monitoring paradigm:

• •IGF-1: Measured at baseline, weeks 4, 12, 26, 52. Target: maintain within age/sex-adjusted normal range (not to exceed 2 SD above mean)
• •Fasting glucose: Baseline and periodic (GH-mediated insulin resistance monitoring)
• •Triglycerides: Baseline and weeks 12, 26 (often a secondary endpoint)
• •CT scan VAT area: Baseline and week 26 (primary endpoint measurement)
• •Waist circumference: Baseline and weeks 12, 26, 52
• •Liver function tests: Periodic (standard safety monitoring)

Reported Adverse Event Profile (from Trials)

From FDA-reviewed Phase III data:

• •Injection site reactions (pain, redness, bruising): Most common AE (~15–25% tesamorelin vs ~10% placebo)
• •Peripheral edema: Approximately 4–6% (GH class effect)
• •Arthralgia/joint pain: ~1–3% (GH class effect)
• •Glucose elevation: Modest (~6–10 mg/dL mean fasting glucose increase)
• •IGF-1 elevation above ULN: Dose-dependent, managed by dose reduction
• •Antibody formation: Some subjects develop anti-tesamorelin antibodies; generally low titer, non-neutralizing

Contraindications established in Egrifta labeling:

• •Malignancy (active or suspected)
• •Pregnancy
• •Disruption of the hypothalamic-pituitary axis (traumatic brain injury, hypophysitis)
• •Hypersensitivity to tesamorelin or components

Stability, Reconstitution, and Handling Notes

Reconstitution Protocol (from Egrifta SV Package Insert)

The following reflects the approved pharmaceutical product's reconstitution procedure for research reference:

Egrifta SV (2 mg/mL formulation):

1. Allow vials to reach room temperature before mixing

2. The sterile water diluent should be injected into the tesamorelin vial

3. Gently swirl (do not shake) the vial to mix — shaking causes aggregation

4. Reconstituted solution should be clear to slightly opalescent, colorless

5. Inspect for particulates or discoloration before use; discard if present

6. Use reconstituted product within 24 hours when stored at 2–8°C (36–46°F)

Storage Requirements

Unreconstituted:

• •Store at 2–8°C (refrigerated)
• •Protect from light and freezing
• •Original Egrifta: shelf life approximately 24 months from manufacture

After reconstitution:

• •Use within 24 hours
• •Do not re-freeze
• •Do not use solution that has been left at room temperature >24 hours

Stability Degradation Pathways

Tesamorelin's key chemical stability vulnerabilities in research peptide preparation:

• •Oxidation: Methionine residue in GHRH sequence susceptible to oxidation (particularly from dissolved oxygen, metal ions)
• •Deamidation: Asparagine/glutamine residues deamidate over time, particularly at elevated pH or temperature
• •Aggregation: Hydrophobic interactions drive peptide aggregation if shaken or exposed to high temperatures
• •Proteolysis: Enzymatic degradation by proteases; minimized at refrigerated storage and by the N-terminal DPP-IV-resistance modification

For research use, lyophilized peptide stored at −20°C in dark conditions provides optimal long-term stability. Reconstituted material should be used promptly.

IGF-1 Monitoring in Tesamorelin Research

Why IGF-1 Monitoring Matters

Unlike GH secretagogue peptides (GHRPs) that produce rapid, short-lived GH spikes, GHRH analogs including tesamorelin drive sustained upregulation of the GH/IGF-1 axis. IGF-1 — which has a half-life of 12–15 hours — serves as the most reliable integrated marker of GH axis stimulation.

IGF-1 changes in Phase III trials:

• •Mean IGF-1 increase from baseline: approximately 60–150 ng/mL (dose-dependent)
• •Most subjects remained within age-adjusted normal range
• •Subjects with IGF-1 >2× upper limit of normal: dose reduction recommended per protocol
• •IGF-1 returns to baseline within weeks of tesamorelin discontinuation

Interpreting IGF-1 in Context

Age-adjusted IGF-1 reference ranges vary substantially. A 40-year-old male has a different normal range than a 60-year-old female. Research protocols using tesamorelin should apply age/sex-stratified reference ranges when assessing IGF-1 responses, as applying a single normal range can lead to incorrect classification of responses.

Tesamorelin Research Summary: Key Takeaways

Tesamorelin occupies a unique position in GHRH analog research:

• •Only FDA-approved GHRH analog — provides highest-quality human evidence base of any compound in this class
• •Selective visceral fat reduction — demonstrated across multiple Phase III trials with CT-measured endpoints
• •Physiological GH stimulation — preserves pulsatile GH pattern and hypothalamic-pituitary feedback
• •Cognitive research signal — preliminary evidence of benefit in HIV population; mechanism plausible
• •Metabolic complexity — visceral fat benefits partially offset by modest glucose elevation
• •Reversibility — effects reverse within months of discontinuation; chronic use required for sustained effect

For researchers studying the GH axis, body composition, or metabolic effects of GHRH signaling, tesamorelin's established clinical dataset makes it the most research-actionable compound in this peptide class.

---

Internal links:

• •Peptide profile: Tesamorelin
• •GHRH Analogs Compared: Sermorelin vs CJC-1295 vs Tesamorelin
• •Peptide Dosage Calculator
• •IGF-1 Research Profile
• •Sermorelin Research Profile
• •CJC-1295 DAC Research Profile

---

For research purposes only. This article does not constitute medical advice. Tesamorelin (Egrifta SV) is a prescription medication indicated for a specific use in HIV-infected individuals. All referenced studies are cited for scientific education. Researchers should comply with all applicable laws and institutional review requirements when handling peptide compounds.

---

Research Supplier Comparison: Tesamorelin Pricing (2026)

Peptides.SO indexes tesamorelin pricing across 95+ participating suppliers. Per-mg cost is the most meaningful comparison metric since vial sizes range from 1 mg to 100 mg:

*Discounted price shown. Prices reflect platform data and may change; verify at point of purchase.

The per-mg cost ranges from ~$3.60/mg (bulk 100 mg vials) to over $80/mg across 95+ indexed sources. Bulk 20 mg+ vials offer the best per-mg economy for laboratory studies requiring larger quantities. For pilot or single-study use, 2–5 mg vials provide appropriate commitment levels.

For live comparison across all 95+ indexed suppliers: Compare Tesamorelin

---

Clinical Research Foundation: Key Phase 3 Trial Data

Tesamorelin's regulatory approval provides an unusually strong clinical research foundation compared to most research peptides:

ACHIEVE Study (2010) — The Pivotal HIV Lipodystrophy Trial

The two Phase 3 ACHIEVE trials established tesamorelin's efficacy as GHRH analog in metabolic research. Key published findings:

• •Falutz J et al. published the primary Phase 3 results showing significant visceral adipose tissue (VAT) reduction in HIV-positive patients with lipodystrophy ([]())
• •Follow-up analysis demonstrated maintenance of visceral fat reduction with continued treatment

The mechanism: tesamorelin stimulates pulsatile GH release from the anterior pituitary via GHRH receptor (GHRHR) agonism, downstream of which IGF-1 increases, and visceral adipose tissue undergoes preferential lipolysis. The visceral fat specificity (vs. subcutaneous fat) has been a focus of subsequent mechanistic research.

Metabolic Effects Research

Falutz J et al. extended the tesamorelin research to evaluate metabolic parameters beyond body composition in HIV lipodystrophy context ([]()):

• •Triglyceride reduction was a consistent finding in VAT-reduction studies
• •Glucose metabolism effects were modest — distinguishing tesamorelin from the greater metabolic impact seen with GHRP secretagogues

Cognitive Research Applications

An emerging area of tesamorelin research is its effects on brain structure and cognitive function. Phase 3 trial data showed benefits in Phase 3 HIV populations ([]()), and subsequent research has explored tesamorelin's effects on hippocampal volume and cognitive measures in non-HIV aging populations.

The mechanistic hypothesis: IGF-1 has established neuroprotective and neurogenic effects in the hippocampus; tesamorelin-driven IGF-1 elevation may translate to neurocognitive benefits that make it an interesting research compound beyond its approved metabolic indication.

---

Comparative GHRH Research: Where Tesamorelin Sits

Understanding tesamorelin's research position requires comparison to related GHRH analogs:

For a full comparison: GHRH Analogs Compared

---

Tesamorelin Research Protocols: What the Literature Uses

Researchers new to tesamorelin often reference the ACHIEVE trial protocols as a starting point:

Published clinical protocols (for context, not as research instructions):

• •Dose: 2 mg/day subcutaneously in ACHIEVE trials
• •Duration: 26–52 weeks in pivotal trials
• •Monitoring: DXA body composition, IGF-1 levels, fasting glucose, lipid panel

For research planning, the ACHIEVE trial publications provide detailed methodology including measurement intervals and biomarker tracking approaches.

---

Reconstitution and Handling

Tesamorelin's reconstitution characteristics are straightforward compared to lipidated GLP-1 analogs:

Optimal reconstitution:

• •Diluent: Sterile water for injection (provided with Egrifta; use equivalent quality for research)
• •Process: Inject diluent against vial wall, swirl gently — do not shake
• •Stability reconstituted: 24 hours at room temperature; or up to 7 days at 4°C

Solubility:

• •Highly water-soluble due to net positive charge at physiological pH
• •Does not require organic co-solvents
• •pH of reconstituted solution: approximately 4.5–5.5 (from TFA salt form)

For general reconstitution guidance: How to Reconstitute Peptides

For storage requirements: Peptide Storage Best Practices

---

Frequently Asked Questions: Tesamorelin Research

Q: What is the GHRH receptor binding affinity of tesamorelin vs. native GHRH?

A: Tesamorelin has binding affinity for GHRHR comparable to native GHRH(1-44). The trans-3-hexenoic acid modification at the N-terminus primarily improves proteolytic stability (resistance to DPP-IV cleavage at the N-terminal Tyr-Ala) without significantly altering receptor binding kinetics. This combination — preserved receptor pharmacology + improved metabolic stability — is the key to tesamorelin's longer effective duration vs. native GHRH.

Q: Can tesamorelin be used to study GH pulsatility?

A: Yes — tesamorelin's mechanism (GHRHR agonism) preserves the pulsatile pattern of GH release, unlike GH secretagogues (GHRPs) that stimulate through the ghrelin receptor and can produce more sustained GH elevations. For research on GH pulsatility and its downstream effects, tesamorelin or sermorelin are the most pharmacologically appropriate tools.

Q: How does tesamorelin's FDA approval affect research access compared to non-approved peptides?

A: FDA approval means tesamorelin is a scheduled pharmaceutical product when used as a drug for human treatment — it requires a prescription. However, research-grade tesamorelin purchased from analytical or research suppliers for non-clinical (laboratory, animal model) research does not require prescription. The approval also means tesamorelin has more extensive published safety and efficacy data than most research peptides, making it an attractive compound for well-characterized research.

Q: Is tesamorelin's research use limited to HIV/lipodystrophy models?

A: Not at all. While the approved indication is HIV-associated lipodystrophy, tesamorelin is researched across GH axis biology, body composition, metabolic syndrome, cognitive function, and as a comparator for novel GHRH analogs. Its Phase 3 clinical data provides strong positive control data for GH axis research in general.

Q: What are the key differences between tesamorelin and sermorelin for GH axis research?

A: The primary distinctions are sequence length, half-life, and evidence base. Tesamorelin uses the full 44-amino-acid GHRH sequence with an N-terminal trans-3-hexenoic acid modification (half-life ~30–45 min); sermorelin is the truncated N-terminal 29 amino acids (half-life ~10–20 min). Both preserve pulsatile GH release. The critical difference: tesamorelin has two Phase III RCTs and FDA approval (Egrifta SV), while sermorelin's clinical data dates from the 1990s with a narrower evidence base. For metabolic research, tesamorelin's dataset is significantly deeper.

Q: What PMIDs should researchers cite for tesamorelin's Phase III clinical data?

A: The core Phase III dataset: Falutz et al. (2007), — the pivotal RCT showing VAT reduction in HIV lipodystrophy; Falutz et al. (2010), — confirming long-term VAT effects; Falutz et al. (2014), — metabolic parameter analysis. For cognitive research: Falutz et al. (2016),. These four publications represent the published Phase III-derived evidence base for tesamorelin.

Q: How should researchers interpret IGF-1 changes during tesamorelin administration?

A: IGF-1 elevation is an expected, on-target pharmacodynamic response — not an adverse event. In Phase III trials, mean IGF-1 increased to ~1.3× baseline with 2 mg/day dosing, remaining within the upper-normal physiological range for most subjects. IGF-1 serves as the primary biomarker of GH axis stimulation. Researchers should measure fasting IGF-1 at baseline and periodically during studies, interpreting values against age- and sex-adjusted reference ranges. Values consistently above the upper limit of normal suggest dose adjustment in clinical contexts.

---

Related Resources

• •Sermorelin Research Profile — The original GHRH analog, comparative reference
• •GHRH Analogs Compared — Full comparison including CJC-1295
• •How to Reconstitute Peptides — Step-by-step protocol
• •Peptide Storage Best Practices — Temperature and stability requirements
• •Compare Tesamorelin Suppliers — Live pricing comparison

Research Use Only. Tesamorelin as a pharmaceutical (Egrifta/Egrifta SV) requires prescription for human therapeutic use. For laboratory research applications only.